Drug Patent Watch

SEPTEMBER 28, 2023

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceuticals Drugs FDA 59

Drug Patent Watch

JULY 27, 2023

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs FDA 52

Drug Patent Watch

JANUARY 19, 2023

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs FDA 52

Drug Patent Watch

SEPTEMBER 27, 2020

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs FDA 52

Conversations in Drug Development Trends

MAY 14, 2024

By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research. Common goals empower change.

Disease 81

Disease Clinical Trials Trials Pharmaceutical Companies 81

Drug Target Review

AUGUST 6, 2024

A number of areas represent significant opportunities for Antibody Drug Conjugates (ADCs) beyond oncology, leveraging their ability to deliver therapeutic agents specifically to diseased cells or tissues while minimising off-target effects. Oncology also offers high returns and the opportunity to address severe, life-threatening conditions.

Therapies 119

Therapies Pharmaceutical Companies Disease Treatment 119

Drug Patent Watch

JULY 26, 2024

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The protection […] Source

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs Disease 52

Drug Target Review

JANUARY 8, 2024

It is no mystery that as we age our health starts to deteriorate, and we become increasingly susceptible to diseases. Through years of scientific exploration and research, we now know there are several biological changes that make our bodies more susceptible to disease or injury, and we can target those with therapeutic interventions.

Science 145

Science Disease FDA Approval Clinical Trials 145

Drug Patent Watch

SEPTEMBER 29, 2022

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs FDA 40

Drug Patent Watch

JULY 27, 2022

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs FDA 40

Drug Patent Watch

JANUARY 19, 2022

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs FDA 40

Drug Patent Watch

SEPTEMBER 28, 2021

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs FDA 40

Drug Patent Watch

JANUARY 19, 2021

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs FDA 40

Drug Target Review

MARCH 4, 2025

A personalised approach to obesity treatment Traditional obesity treatments have often followed a one-size-fits-all model, despite mounting evidence that obesity is not a singular disease but rather a collection of subtypes. This growing health challenge increases the risk of diabetes, heart disease, and other conditions.

Therapies 52

Therapies Treatment Clinical Trials Science 52

Drug Patent Watch

DECEMBER 9, 2024

High-Throughput Screening: Modern Technology Meets Natural Products Advanced technologies now allow researchers to rapidly test thousands of natural compounds against specific disease targets. This approach has led to the discovery of numerous potential drug candidates.

Drugs 97

Drugs Drug Development Pharmaceuticals Production 97

Conversations in Drug Development Trends

MAY 14, 2024

By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research. Common goals empower change.

Disease 52

Disease Clinical Trials Trials Pharmaceutical Companies 52

Broad Institute

DECEMBER 18, 2023

Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely. Studies of Alzheimer's disease are teaching us that it's possible to measure some clinically important CSF biomarkers in blood.

Drug Development 130

Drug Development Clinical Trials Drugs Disease 130

The Pharma Data

SEPTEMBER 3, 2020

Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Source link.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

Advarra

AUGUST 16, 2022

A rare, or orphan, disease by definition affects a small percentage of the population — fewer than 200,000 people in the U.S. But the numbers add up, and taken together, rare diseases impact an estimated 30 million Americans. Since then, the FDA has significantly changed its approach to rare and orphan diseases.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

Drug Target Review

SEPTEMBER 19, 2024

Based on Nobel Prize-winning research, IRLAB has grown rapidly to become recognised and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders, especially Parkinson’s disease (PD). The treatment often initially provides good symptom relief and those affected by the disease can live a largely normal life.

Disease 52

Disease Drugs Treatment Drug Development 52

Drug Target Review

SEPTEMBER 19, 2023

The chips can be modelled with primary cells, IPS derived stem cells or patient derived cells and potentiates to unlock molecular mechanisms that drive the disease pathophysiology, holding a greater promise. The first successful chip adaptation to a lung model was first described in 2010 by Donald Ingber, a bioengineer at Wyss institute.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

DrugBank

OCTOBER 4, 2024

Emerging Markets Emerging markets, particularly in Asia and Latin America, have become increasingly attractive destinations for pharmaceutical M&A activity. The growing middle class and government initiatives to improve access to medicines have created an ecosystem for pharmaceutical companies seeking growth opportunities.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

KIF1A

JULY 1, 2023

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. But promising drugs that didn’t make the cut for treating one disorder may still be effective for other rare diseases. What’s a pre-print?

Small Molecule 98

Small Molecule FDA Approval Disease Pharmaceutical Companies 98

Drug Target Review

DECEMBER 11, 2024

This shift in focus is especially critical in toxicology, where accurate target analysis plays a vital role in identifying toxic effects and ensuring patient safety, particularly as the field transitions from traditional drugs to the promising realm of biotherapeutics, especially for rare diseases.

International 52

International Laboratories Drugs Pharmacokinetics 52

The Pharma Data

JANUARY 5, 2021

RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases. We intend to use PWS as the anchor indication and will further investigate additional orphan disease opportunities in due course.”. Disease Highlights.

Disease 52

Disease FDA Approval Clinical Trials Trials 52

NIH Director's Blog: Drug Development

APRIL 7, 2015

Credit: NIH Alzheimer’s disease research is among the many areas of biomedical science that Senator Barbara Mikulski has championed during her nearly 40 years on Capitol Hill. Caption: Here I am with Senator Barbara Mikulski (center) and NCATS Director Chris Austin (right). population continues to age.

Disease 40

Disease Drugs Clinical Trials Science 40

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. and are linked to the company’s project AD1503.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

SCIENMAG: Medicine & Health

OCTOBER 4, 2023

In an article revealed today in Nature, scientists from deCODE Genetics, a subsidiary of the pharmaceutical company Amgen, demonstrated how plasma proteomics can contribute to a better understanding of diseases. Measuring a great […]

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Disease 52

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

Quanticate

SEPTEMBER 27, 2024

Each scientific field whether it be oncology , dermatology , rare disease , or others, presents unique challenges and opportunities that are crucial to improving patient outcomes, as well as guiding the efforts of researchers, physicians, and pharmaceutical companies in advancing healthcare solutions globally.

Clinical Research 52

Clinical Research Research Pharmaceutical Companies Science 52

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? There are a lot of drug development challenges that are, in some cases, unique to neuroscience, including neurological diseases, psychiatric disorders, and rare diseases affecting the nervous system.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

DrugBank

APRIL 12, 2024

Harnessing AI in Drug Discovery: A Snapshot AI’s penetration into healthcare and pharmaceuticals, particularly through machine learning algorithms and generative models, is profound.

Drugs 98

Drugs Clinical Trials Pharmaceutical Companies Pharmaceuticals 98

Drug Target Review

JULY 18, 2023

Where AI can help us is to interrogate that biological question and make sure that we are identifying and drugging disease modifying targets in the right way.” With support from pharmaceutical companies, ultimately, the answer to this question should be yes. This means that we are not doing something right.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

PPD

AUGUST 16, 2023

The study’s objective was to supplement the findings of PPD surveys conducted in 2020 and 2021 that examined similar issues from the perspective of sponsor pharmaceutical companies. However, the accessibility of advanced technologies enables the expansion of DCT models to other disease states.

Clinical Trials 98

Clinical Trials Trials Clinical Research FDA 98

DrugBank

SEPTEMBER 19, 2024

Another example is esomeprazole , a medication for treating gastroesophageal reflux disease that utilizes an enteric-coated delayed-release capsule to ensure the medication bypasses the stomach and dissolves directly in the small intestine, maximizing its effectiveness in reducing stomach acid production.

Drugs 98

Drugs Pharmacokinetics Treatment Disease 98

The Pharma Data

SEPTEMBER 22, 2020

“We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications,” said Matt Cooper, chief executive officer of Inflazome. and IL-18, which are believed to be a driving force behind several chronic inflammatory conditions. Source link.

Pharma Companies 52

Pharma Companies Small Molecule Pharmaceutical Companies Disease 52